Showing 3291-3300 of 7283 results for "".
- FDA Approves Dupixent for Children Aged 6 to 11 Years with Moderate-to-Severe ADhttps://practicaldermatology.com/news/fda-approves-dupixent-for-children-aged-6-to-11-years-with-moderate-to-severe-ad/2460404/The US Food and Drug Administration (FDA) gave its nod to Dupixent (dupilumab) for children aged 6 to 11 years with moderate-to-severe atopic dermatitis (AD). Dupixent comes in two doses, prescribed based on weight (300 mg every four weeks for children ≥15 to <30 kg and 200 mg eve
- Congrats: Dr. Paul Bergstresser Receives ASA’s David Martin Carter Mentor Awardhttps://practicaldermatology.com/news/congrats-dr-paul-bergstresser-receives-asas-david-martin-carter-mentor-award/2460401/Dr. Paul Bergstresser of UT Southwestern Medical Center in Dallas, Texas is the recipient of the American Skin Association’s (ASA) 2020 David Martin Carter Mentor Award Since 1989, ASA's David Martin Carter Mentor Award has honored members of the derma
- New Medscape Physician Compensation Report: Derms Earn About $411Khttps://practicaldermatology.com/news/new-2020-medscape-physician-compensation-report-derms-earn-about-411k/2460394/The 2020 Medscape Physician Compensation Report is out, and it shows that dermatologists earn an average of $411K per year, down 2 percent from 2019. Plastic surgeons earn $479K per year on average, up 2 percen
- May Is Ichthyosis Awareness Monthhttps://practicaldermatology.com/news/may-is-ichthyosis-awareness-month/2460390/May is Ichthyosis Awareness Month, and Timber Pharmaceuticals, LLC is highlighting the efforts of the
- Accure Laser Gets CE Mark for Acne Treatmenthttps://practicaldermatology.com/news/accure-laser-gets-ce-mark-for-acne-treatment/2460386/Accure Acne, Inc. now has a European CE mark for its groundbreaking Accure Laser™ system to treat patients with moderate acne vulgaris. The Accure Laser is the first commercially-developed light-based platform in the world to selectively target and injure sebaceous glands. Fo
- Survey: Social Media Isn’t All That Helpful for Growing Your Derm Practicehttps://practicaldermatology.com/news/survey-social-media-isnt-all-that-helpful-for-growing-your-derm-practice/2460384/Patients often do not take social media into consideration when looking for a dermatologist, according to a survey from researchers at the George Washington University. The survey appears in the Journal of Drugs in Derma
- Cabaletta Bio Receives FDA Fast Track Designation for DSG3-CAART for the Treatment of mPVhttps://practicaldermatology.com/news/cabaletta-bio-receives-fda-fast-track-designation-for-dsg3-caart-for-the-treatment-of-mpv/2460383/The U.S. Food and Drug Administration (FDA) granted Cabaletta Bio’s DSG3-CAART (Desmoglein 3 Chimeric AutoAntibody Receptor T cells) Fast Track Designation for improving healing of mucosal blisters in patients with mPV. DSG3-CAART is designed to specifically target the cause of mP
- Positive Top-Line Results Seen for Otezla in Mild-To-Moderate Plaque Psoriasishttps://practicaldermatology.com/news/positive-top-line-results-seen-for-otezla-in-mild-to-moderate-plaque-psoriasis/2460382/Amgen’s Otezla produces significant improvements in measures of mild-to-moderate psoriasis, compared with placebo, according to a top-line results from the ADVANCE trial. ADVANCE is a Phase 3, multicenter, randomized, placebo-controlled, double-blind study to assess the efficacy o
- Med Spas May Need a Post-COVID-19 Facelifthttps://practicaldermatology.com/news/medspas-may-need-a-post-covid-19-facelift/2460370/Everyone is feeling anxious about returning to public spaces including spas following the COVID-19 pandemic, according to the new ISPA Consumer Snapshot Initiative. “We know that COVID-19 has created a lot of uncertainty in many industries, including the spa industry,” says
- Urgent: CMS Extends MIPS Extreme and Uncontrollable Circumstances Exception Application Until 4/30/2020https://practicaldermatology.com/news/urgent-cms-extends-mips-extreme-and-uncontrollable-circumstances-exception-application/2460369/The Centers for Medicare & Medicaid Services (CMS) re-opened the 2019 MIPS Extreme and Uncontrollable Circumstances Exception Application to individuals, groups, and virtual groups, including those who have already submitted data, due to the 2019 Novel Coronavirus (COVID-19) pandemi